

# Molecular BioSystems

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).


Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



[www.rsc.org/molecularbiosystems](http://www.rsc.org/molecularbiosystems)

Table of contents:

This study identified the potential biomarkers in urine, plasma and feces of high fructose-fed rats by using  $^1\text{H}$  NMR-based metabonomics.



# An integrated metabonomic approach to study metabolic profiles in insulin resistance rat model induced by high fructose

*Yongxia Yang<sup>a\*</sup>, Linlin Wang<sup>a,b#</sup>, Shumei Wang<sup>b</sup>, Rongbo Huang<sup>a</sup>, Lingyun Zheng<sup>a</sup>,*

*Shengwang Liang<sup>b</sup>, Lei Zhang<sup>a</sup>, Jingfen Xu<sup>a</sup>*

<sup>a</sup> School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China

<sup>b</sup> Department of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China

**\*Corresponding author:**

Associate Prof. Yongxia Yang: School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China; Tel: 86-(0)20-3935-2197, Fax: 86-(0)20-3935-2186, E-mail: sheepma@163.com

<sup>#</sup> contributed equally to this work.

**Abstract**

Insulin resistance (IR) is one of the common risk factors for the development of metabolic diseases, and gradually becomes a hot issue of research. It was reported that excessive feeding of high fructose induced insulin resistance for both humans and rats. The aim of this study was to investigate the progression of IR and identify potential biomarkers in urine, plasma and fecal extracts of high fructose-fed rats by using  $^1\text{H}$  NMR-based metabonomics approach. The biochemical analysis was also performed. The plasma levels of pyruvate and lactate in the IR model rats reduced significantly, as well as the decrease of citrate and  $\alpha$ -KG in urine and succinate in fecal, suggesting the perturbation of energy metabolism. The decreased level of taurine in urine and fecal extracts during the whole experiment, together with increased urinary level of creatine/creatinine revealed liver and kidney injury. Decreased levels of choline containing metabolites in urine and increased level of betaine in urine and plasma demonstrated altered transmethylation. The changes of hippurate, acetate, propionate and n-butyrate suggested the disturbance of intestinal flora in IR rats. This study indicated that  $^1\text{H}$  NMR-based metabonomics can provide biochemical information for the progression of IR and offers a non-invasive means to the discovery of potential biomarkers.

Key words:  $^1\text{H}$  NMR; Metabonomics; Insulin resistance; Fructose; Pattern recognition

## 1 **1. Introduction**

2 The incidence and prevalence of insulin resistance (IR) associated diseases are  
3 occurring at alarmingly increasing rates with frightful consequences to the health of  
4 human worldwide.<sup>1</sup> Insulin resistance, the decreased response of peripheral tissue to  
5 normal insulin levels, is known as the underlying cause of type 2 diabetes mellitus  
6 (DM), cardiovascular disease and metabolic syndrome (MS).<sup>2</sup> One of the main driving  
7 forces for the increased prevalence of MS is modern westernized diets associated with  
8 the dramatic rises in obesity. Diets high in saturated fats and fructose have been  
9 shown to induce weight gain, insulin resistance and hyperlipidemia in humans and  
10 animals.<sup>3,4</sup> For thousands of years humans have consumed fructose from its natural  
11 sources, i.e. fresh fruits and vegetables, in a range of 16-20 g per day. However, the  
12 significant increase in added fructose from Westernized diets has increased the daily  
13 consumptions amounting to 85-100 g of fructose per day.<sup>5</sup> It has been postulated that  
14 such increased consumption would contributed to obesity, type 2 diabetes and MS.<sup>6</sup>  
15 Studies have showed that administration of a high fructose diet to normal rats induced  
16 IR and MS.<sup>7-9</sup> Human studies have also reported that dietary fructose may increase  
17 caloric intake and, consequently, obesity and the associated features of MS.<sup>10</sup>

18 Metabolic disorders were common in IR-correlated diseases including DM and  
19 hyperlipidemia. Cannizzob<sup>11</sup> et al. reported that high fructose induced a marked  
20 increase in plasma glucose, insulin and triglycerides, provoked vascular remodeling  
21 and enlarged atherosclerotic lesion in aortic and carotid arteries. High fructose diet  
22 can also induce severe liver steatosis, with significantly higher cholesterol level.<sup>12</sup>  
23 Therefore, research of metabolic changes of fructose-induced IR rat models is most  
24 important for understanding the metabolic mechanism for IR-based metabolic  
25 diseases.

26 With the development of new analytical techniques, metabonomics offers an  
27 alternative method for monitoring the biochemical changes induced by endogenous  
28 and exogenous factors,<sup>13,14</sup> which was proved to be an effective and nondestructive  
29 method to probe the metabolic responses within a whole organism. In conjunction  
30 with pattern recognition (PR) data analysis techniques, such as principal component  
31 analysis (PCA) and partial least squares projection on discriminant analysis (PLS-DA),  
32 NMR-based metabonomics has been widely applied in many metabolic diseases.<sup>15,16</sup>

33 In this study, we established the IR model induced by feeding of 10% fructose  
34 drinking water, similar with the modeling method preciously reported.<sup>17</sup> The aim of  
35 this research is to investigate the time-dependent metabolic changes of IR model by  
36 an integrated metabonomic approach on urine, plasma and feces. Meanwhile, the  
37 blood glucose level and IR index were determined by biochemistry methods.

## 38 **2. Materials and Methods**

### 39 2.1 Animal experiment and sample collection

40 Twenty male Wistar rats (weighting 180-200g) were purchased from Medical  
41 Laboratory Animal Center of Sun Yat-Sen University, and housed in a well-ventilated  
42 animal experimental laboratory, with a 12 h light/dark cycle, a temperature of  $25 \pm$   
43  $1$  °C, and a relative humidity of  $50 \pm 10\%$ . This study was reviewed and approved by  
44 the Ethics Committee of Guangdong Pharmaceutical University. Food and pure water  
45 were freely provided. After acclimatization for one week, the rats were randomly  
46 divided into two groups (n=10/group), i.e. control group and fructose-fed group. The  
47 control rats were administrated with distilled water for 8 weeks. The model rats were  
48 consecutively fed with 10% fructose water in the whole procedure for 8 weeks. This  
49 IR modeling method was according to the method of Mahmoud.<sup>17</sup>

50 During the experimental period, feces and urine samples of each group were  
51 collected at the end of 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week. Urine sample collection was carried out  
52 overnight for 12h using metabolism cages. 100  $\mu$ L of 1% Sodium azide was pipetted  
53 into collection container for anti-bacteria before urine collection. Fecal samples were  
54 taken immediately prior to the rats being removed from the metabolic cages. All the  
55 samples were stored at -80°C for NMR determination. Blood samples were collected  
56 by orbital venous plexus at the end of 4<sup>th</sup> week just for clinical chemistry analysis  
57 after fasting for 12 h. In addition, plasma samples at the end of 8<sup>th</sup> week were  
58 collected for clinical chemistry analysis and NMR analyses.

## 59 2.2 Sample preparation

### 60 2.2.1 Urine and plasma samples preparation

61 The urine and plasma samples were thawed at room temperature just prior to NMR  
62 analysis. 300  $\mu$ L of sample was mixed with 200  $\mu$ L of phosphate buffer (0.2 M  
63 Na<sub>2</sub>HPO<sub>4</sub>/ NaH<sub>2</sub>PO<sub>4</sub>, pH 7.4) to minimize chemical shift variations and then  
64 centrifuged (14,000 g, 10 min, 4 °C) to remove any precipitates. The supernatant was  
65 then pipetted into 5 mm NMR tube and 80  $\mu$ L of D<sub>2</sub>O containing 0.05% sodium  
66 3-trimethylsilyl-(2, 2, 3, 3-<sup>2</sup>H<sub>4</sub>)-1-propionate (TSP) was added.

### 67 2.2.2 Fecal extracts preparation

68 Fecal extract method for NMR analyses was referenced to the reported result by Y  
69 Zhao.<sup>18</sup> Briefly, fecal extracts were prepared by mixing 70 mg of fecal samples with  
70 700  $\mu$ L of phosphate buffer (0.1 M Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> = 4/1, pH = 7.4).

71 After vortex mixing, the samples were subjected to freeze-thaw treatments for 3 times  
72 and followed with ultrasonication cycles for 10 times, then collected the supernatant.

73 The residuals were subjected to the extract method mentioned above once again. The  
74 supernatants were merged and centrifuged (14,000 g, 10 min, 4 °C). 400  $\mu$ L of

75 supernatant was transferred into 5 mm NMR tube and 100  $\mu\text{L}$  of  $\text{D}_2\text{O}$  containing  
76 0.05% sodium 3-trimethylsilyl-(2, 2, 3, 3- $^2\text{H}_4$ ) -1-propionate (TSP) was added.<sup>18</sup>

### 77 2.3 $^1\text{H}$ NMR spectroscopy

78  $^1\text{H}$  NMR spectra of all samples were collected at 298K on a Bruker Avance III 500  
79 MHz spectrometer. The  $^1\text{H}$  NMR spectra of urine and fecal extracts samples were  
80 recorded using the water-presaturated standard one-dimensional NOESYPR1D pulse  
81 sequence (recycle delay- $90^\circ$ - $t_1$ - $90^\circ$ - $t_m$ - $90^\circ$ -acquisition) for representation of the total  
82 metabolite compositions. 64 transients were collected into 32k data points using a  
83 spectral width of 10 kHz with a relaxation delay of 3 s, and mixing time ( $t_m$ ) of 100  
84 ms.  $t_1$  was set to 3  $\mu\text{s}$ . The  $^1\text{H}$  NMR spectra of plasma samples were recorded using  
85 the water-suppressed standard one-dimensional Carr-Purcell-Meiboom-Gill (CPMG)  
86 spin-echo pulse sequence (RD- $90^\circ$ -( $\tau$ - $180^\circ$ - $\tau$ ) $_n$ -acquisition) in order to reduce the  
87 peaks overlapping. 128 transients were collected into 32k data points using a spectral  
88 width of 10 kHz with a relaxation delay of 3 s, and total echo time was 100 ms. The  
89 free-induction decays (FIDs) were multiplied by an exponential function with a  
90 line-broadening factor of 0.3 Hz before Fourier transformation. The chemical shifts of  
91 spectra were referenced to the TSP at  $\delta$  0.00.

### 92 2.4 Pattern recognition and statistical analysis

93 All the spectra were phase- and baseline-corrected manually, and then bucketed and  
94 automatically integrated with an automation routine in AMIX. Each  $^1\text{H}$  NMR  
95 spectrum was segmented into regions of 0.005 ppm (plasma and urine) or 0.02 ppm  
96 (fecal extracts). The region of  $\delta$  4.6-5.2 was discarded to eliminate the effects of water  
97 suppression. The integrals of these buckets covered the region  $\delta$  0.5-9.0 and were  
98 normalized to the total sum of the spectral integrals, as variables for PCA and



99 PLS-DA. For urine spectra, the region containing urea ( $\delta$  5.2-6.2) was also discarded  
100 to eliminate the urea signals.

101 All  $^1\text{H}$  NMR spectra were submitted to PCA and PLS-DA using the software  
102 Simca-P<sup>+</sup> 12.0 (Umetrics, Sweden). Scores plots, highlighting inherent clustering  
103 trends of the samples, and loadings plots, providing potential biomarkers, were  
104 visualized. Statistical analyses were performed with an analysis of variance. A  $p < 0.05$   
105 was considered significant.

#### 106 2.5 Weight measurement, blood glucose and IR index assessment

107 At the end of 4<sup>th</sup> and 8<sup>th</sup> week, the weight of each rat was measured. Fasting blood  
108 glucose was determined colorimetrically by using a Randox reagent kit, according to  
109 the method of Barham and Trinderb.<sup>19</sup> Blood insulin levels were assayed with a  
110 sandwich ELISA (Millipore), which used a microtiter plate coated with mouse  
111 monoclonal anti-rat insulin antibody. The homeostasis model assessment for insulin  
112 resistance index was calculated according to the following equation:<sup>20</sup>

$$113 \text{HOMA-IR} = \text{glucose concentration (mmol/L)} \times \text{insulin (mU/L)} / 22.5.$$

114 Independent sample *t* test was conducted to compare the biochemical data of IR  
115 model rats and control rats.

### 116 3. Results

#### 117 3.1 Influence of fructose feeding on weight, blood glucose and insulin resistance

118 The fructose feeding had induced weight gain at the end of 4<sup>th</sup> and 8<sup>th</sup> week (Table  
119 1), while it had no obvious influence on blood glucose, which was similar with the  
120 results reported.<sup>17</sup> IR index increased after 4 weeks fructose feeding and continued to  
121 elevate at the end of 8<sup>th</sup> week with statistical significance. So fructose feeding had  
122 induced insulin resistance successfully.

123

124 Table 1 Summary of weight, glucose level and IR index data at the end of 4<sup>th</sup> and 8<sup>th</sup> week.

Group	4 <sup>th</sup> week			8 <sup>th</sup> week		
	Weight (g)	Glucose (mmol/L)	IR	Weight (g)	Glucose (mmol/L)	IR
Control	314.43±7.44	4.84±0.73	4.80±0.13	406.12±8.58	4.92±0.43	4.95±0.65
Model	343.87±18.61*	5.24±0.84	7.55±0.31*	464.45±22.43*	5.26±0.49	10.32±0.37**

125 Values are presented as means ± SD. \*: to compare with controls \**p*<0.05; \*\**p*<0.01.126 3.2 <sup>1</sup>H NMR Spectroscopy and pattern recognition analysis of urine

127 Figure 1 showed the representative 500 MHz urinary <sup>1</sup>H NMR NOESYPR1D  
 128 spectra of rats from control and fructose-fed IR group at the end of 8<sup>th</sup> week.

129 Assignments of endogenous metabolites involved in <sup>1</sup>H-NMR spectra were based on

130 the literature<sup>21</sup> and confirmed by 2D spectroscopy. The urinary NMR spectra were

131 dominated by 2-hydroxybutyrate, isoleucine, leucine, valine, 3-hydroxybutyrate,

132 lactate, alanine, acetate, N-acetylglycoprotein, acetone, acetoacetate, succinate,

133 α-ketoglutaric acid (α-KG), citrate, dimethylglycine (DMG), creatine/creatinine,


134 tyrosine, choline, PC/GPC, TMAO/betaine, taurine, glycine, glycerol, α-glucose,

135 β-glucose, phosphoethanolamine, hippurate, fumarate, 4-hydroxyphenyllactate,

136 phenylacetyl glycine and formate. Visually, the urinary metabolic profiles did not

137 showed obvious discrimination between these two groups. Therefore, we did the

138 multivariate data analysis to obtain the metabolic markers in IR models.




139  
 140 **Figure 1** Representative urine <sup>1</sup>H NMR spectra from A: controls, B: fructose-fed IR rats at the end  
 141 of 8<sup>th</sup> week. Keys: 1. 2-hydroxybutyrate; 2. isoleucine; 3. leucine; 4. valine; 5. 3-hydroxybutyrate;

142 6. lactate; 7. alanine; 8. acetate; 9. N-acetylglycoprotein; 10. acetone; 11. acetoacetate; 12.

143 succinate; 13.  $\alpha$ -ketoglutaric acid ( $\alpha$ -KG); 14.citrate; 15. dimethylglycine (DMG);  
144 16.creatine/creatinine; 17. tyrosine; 18. choline; 19. PC/GPC; 20. TMAO/betaine; 21. taurine; 22.  
145 glycine; 23. glycerol; 24.  $\alpha$ -glucose; 25.  $\beta$ - glucose; 26. phosphoethanolamine; 27. hippurate; 28.  
146 fumarate; 29. 4-hydroxyphenylactate; 30. phenylacetyl glycine; 31. formate.

147 Figure 2A1 showed the score plot of PCA representing the distribution of all the  
148 urinary samples at the end of 4<sup>th</sup> (●), 6<sup>th</sup> (□) and 8<sup>th</sup> (▲) week in IR group. It could be  
149 seen that there were obvious distribution trajectory of samples, as the arrow showed.  
150 With the increase of feeding time, the distribution of samples moved from right to left  
151 along t1 dimension, and then moved upward along t2 dimension. It might be  
152 concluded from the analysis results that urine metabolic profiles could reflect the  
153 metabonomic perturbations at different feeding time. PCA was also performed on the  
154 spectra data of control rats. The score plot didn't show obvious classification for the  
155 samples at three time points (Fig. 2A2). The PCA results revealed that metabolic  
156 variations in model rats were closely correlated with high fructose feeding.

157 PLS-DA models were established respectively for the classification between  
158 controls and fructose-fed IR rats in order to further detect the associated potential  
159 biomarkers. The distinct classifications between controls and IR rats at 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup>  
160 week were shown in the score plots (Fig. 2B1, C1 and D1). From the coefficient  
161 -coded loading plot (Fig. 2B2), it was found the levels of acetate, TMAO/betaine and  
162 creatine/creatinine increased, while citrate,  $\alpha$ -KG and taurine decreased in the samples  
163 of fructose-fed models at the end of 4<sup>th</sup> week. In addition to the metabolic changes  
164 mentioned above, the increased level of hippurate and decreased levels of choline and  
165 PC/GPC was found at the end of 6<sup>th</sup> week (Fig. 2C2), while the changes of acetate,  
166 TMAO/betaine and hippurate were not evident at the end of 8<sup>th</sup> week (Fig. 2D2).



167

168 **Figure 2** Multivariate analyses of urinary  $^1\text{H}$  NMR spectra data at the end of 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week.169 A1, A2: PCA score plots of IR model ( $R^2X=73.1\%$ ,  $Q^2=50.1\%$ ) and control ( $R^2X=75.4\%$ ,170  $Q^2=45.3\%$ ) rats at three time points, respectively. B1, B2: Score plot and coefficient-coded loading171 plot of PLS-DA between control and model groups at the end of 4<sup>th</sup> week ( $R^2X=53.8\%$ ,172  $Q^2Y=62.5\%$ ). C1, C2: Score plot and coefficient-coded loading plot of PLS-DA between control173 and model groups at the end of 6<sup>th</sup> week ( $R^2X=68.8\%$ ,  $Q^2Y=79.4\%$ ). D1, D2: Score plot and174 coefficient-coded loading plot of PLS-DA between control and model groups at the end of 8<sup>th</sup>175 week ( $R^2X=67.2\%$ ,  $Q^2Y=84.6\%$ ).

176 Table 2 summarized the statistical analysis results of the normalized integrals of  
 177 metabolites screened out in Fig. 2, accounting for the metabolites differentiation  
 178 between two groups at the end of 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week.


179 Table 2 The statistical analysis results of the metabolites in urine of IR model group at the end of  
 180 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week.

metabolites	chemical shift	variations		
		4 <sup>th</sup> week	6 <sup>th</sup> week	8 <sup>th</sup> week
acetate	1.92(s)	↑*	↑*	-
α-KG	2.45(t)	↓*	↓**	↓**
	3.01(t)			
citrate	2.56(d)	↓*	↓**	↓**
	2.72(d)			
creatinine/creatinine	3.03(s)	↑*	↑*	↑**
	4.05(s)			
choline	3.21(s)	-	↓*	↓**
PC/GPC	3.23(s)	-	↓*	↓**
taurine	3.27(t)	↓*	↓**	↓**
	3.43(t)			
TMAO/betaine	3.27(s)	↑*	↑*	-
hippurate	3.97(s)	-	↑*	-

181 \* : to compare with controls \*  $p < 0.05$ ; \*\*  $p < 0.01$ .


### 182 3.3 <sup>1</sup>H NMR spectroscopy and pattern recognition analysis of plasma

183 Two typical <sup>1</sup>H CPMG NMR spectra of plasma from control and model rats at 8<sup>th</sup>  
 184 week were shown in Fig.3. The NMR resonances were assigned according to the  
 185 literature<sup>22</sup> and confirmed by 2D spectroscopy. We observed the metabolites including  
 186 lipids, amino acids (leucine, isoleucine, valine, alanine and lysine), lactate and  
 187 glucose, etc. The score plot of PLS-DA (Fig.4A1) showed the clear separation  
 188 between the controls and IR rats. From the coefficient-coded loading plot (Fig.4A2),  
 189 the elevated levels of lipid (mainly LDL/VLDL), alanine, acetate, taurine,  
 190 TMAO/betaine and glycine, as well as decline in the levels of lactate, pyruvate and  
 191 glycerol, were found in the plasma samples of IR models at the end of 8<sup>th</sup> week.



192

193 **Figure 3** Representative plasma  $^1\text{H}$  NMR spectra from A: controls, B: fructose-fed IR rats at the  
 194 end of 8<sup>th</sup> week. Keys: 1. Lipid (mainly LDL/VLDL); 2. isoleucine; 3. leucine; 4. valine; 5. lactate;  
 195 6. alanine; 7. acetate; 8. N-acetyl glycoprotein; 9. O-acetyl glycoprotein; 10. acetone; 11.  
 196 acetoacetate; 12. pyruvate; 13. glutamine; 14. citrate; 15. creatine/creatinine; 16. choline; 17.  
 197 GPC/PC; 18. taurine; 19. TMAO/betaine; 20. glycine; 21. myo-inositol; 22. glycerol; 23.  
 198  $\alpha$ -glucose; 24.  $\beta$ -glucose; 25. unsaturated lipid; 26. tyrosine; 27. 1-methylhistidine; 28.  
 199 phenylalanine.



200

201 **Figure 4** PLS-DA of plasma  $^1\text{H}$  NMR spectra data from control and fructose-fed IR rats at the end  
 202 of 8<sup>th</sup> week ( $R^2\text{X}=66.4\%$ ,  $Q^2\text{Y}=49.5\%$ ). A1: score plot; A2: coefficient-coded loading plot.

203 Table 3 summarized the statistical analysis results of the metabolites screened out  
 204 in Fig. 4, accounting for the differentiation between two groups at 8<sup>th</sup> week.

205

206

207

208


209 Table 3 The statistical analysis result of the metabolites in plasma of control and model group at  
210 8<sup>th</sup> week.

metabolites	chemical shift	variations
		8 <sup>th</sup> week
lipid	1.27(m)	↑**
lactate	1.33(d)	↓**
alanine	1.48(d)	↑*
acetate	1.92(s)	↑**
pyruvate	2.37(s)	↓*
TMAO/betaine	3.27(s)	↑**
taurine	3.43(t)	↑*
glycine	3.54(s)	↑*
glycerol	3.56(dd)	↓**

211 \*: to compare with controls \*  $p < 0.05$ ; \*\*  $p < 0.01$ .

### 212 3.4 <sup>1</sup>H NMR Spectroscopy and pattern recognition analysis of fecal extracts

213 Fig.5 showed typical <sup>1</sup>H NMR NOESYPR1D spectra of fecal extracts from control  
214 and model rats at 8<sup>th</sup> week. Assignments of the metabolites involved in <sup>1</sup>H NMR  
215 spectra were based on the literatures<sup>18,23</sup> and confirmed by 2D spectroscopy. We  
216 observed that the main metabolites in the fecal extracts spectra were short chain fatty  
217 acids (SCFAs) such as butyrate, propionate and acetate, amino acids (leucine,  
218 isoleucine, valine, alanine and lysine), uracil, lactate and glucose and so on. In order  
219 to further find out the potential metabolic markers of IR models, we did the  
220 multivariate data analysis.




221 **Figure 5** Representative <sup>1</sup>H NMR spectra of fecal extracts from A: controls, B: fructose-fed IR  
222 rats at the end of 8<sup>th</sup> week. Keys: 1. n-butyrate; 2. isoleucine; 3. leucine; 4. valine; 5. propionate; 6.  
223 α-ketoisovalerate; 7. lactate; 8. alanine; 9. lysine; 10. cadaverine; 11. acetate; 12. isobutyrate; 13.  
224

225 glutamate; 14. succinate; 15. glutamine; 16. aspartate; 17. tyrosine; 18. taurine; 19. glycine; 20.  
226 glycerol; 21.  $\alpha$ -glucose; 22.  $\beta$ -glucose; 23.  $\alpha$ -xylose; 24.  $\alpha$ -arabinose; 25.  $\alpha$ -galactose; 26. uracil;  
227 27. urocanate; 28. fumarate; 29. tryptophan; 30. phenylalanine; 31. histidine.

228 The score plot of PCA represented distribution of the model rats (Fig.6A1), where  
229 the samples at 4<sup>th</sup> week were separated from the ones at 6<sup>th</sup> and 8<sup>th</sup> week along t1  
230 dimension. A classification between 6<sup>th</sup> and 8<sup>th</sup> week was also observed as the arrow  
231 indicated, whereas the control group displayed no significant differences at three time  
232 points (Fig. 6A2). The PCA results indicated that metabolic variations in model rats  
233 could reflect the influence of fructose feeding.

234 PLS-DA models were established respectively for the classification between  
235 controls and fructose-fed IR rats in order to further detect the associated potential  
236 biomarkers respectively. The obvious classifications between controls and IR rats at  
237 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week were shown in the score plots (Fig. 6B1, C1 and D1). From the  
238 coefficient-coded loading plot (Fig. 6B2), it was found the levels of alanine and  
239 glutamate increased, while n-butyrate, acetate, succinate and taurine decreased in the  
240 samples of fructose-fed models at the end of 4<sup>th</sup> week. It was noted that the increased  
241 levels of n-butyrate and isobutyrate, as well as decreased levels of propionate, lactate  
242 and glycerol, were found at the end of 6<sup>th</sup> week (Fig. 6C2). It was also found that  
243 isoleucine/leucine decreased in model rats at the end of 8<sup>th</sup> week, while the change of  
244 succinate was not obvious (Fig. 6D2).





245

246 **Figure 6** Multivariate data analyses of  $^1\text{H}$  NMR spectra of fecal extracts at the end of 4<sup>th</sup>, 6<sup>th</sup> and  
 247 8<sup>th</sup> week. A1, A2: PCA score plots of IR model ( $R^2X=62.7\%$ ,  $Q^2=48.4\%$ ) and control ( $R^2X=49.4\%$ ,  
 248  $Q^2=23.1\%$ ) rats at three time points. B1, B2: Score plot and coefficient-coded loading plot of  
 249 PLS-DA between control and fructose-fed model groups at the end of 4<sup>th</sup> week ( $R^2X=49.7\%$ ,  
 250  $Q^2Y=61.7\%$ ). C1, C2: Score plot and coefficient-coded loading plot of PLS-DA between control  
 251 and fructose-fed model groups at the end of 6<sup>th</sup> week ( $R^2X=86.5\%$ ,  $Q^2Y=80.8\%$ ). D1, D2: Score  
 252 plot and coefficient-coded loading plot of PLS-DA between control and fructose-fed model groups  
 253 at the end of 8<sup>th</sup> week ( $R^2X=63.1\%$ ,  $Q^2Y=47.8\%$ ).

254 Table 4 summarized the statistical analysis results of the normalized integrals of  
 255 metabolites screened out in Fig. 6, accounting for the metabolites differentiation  
 256 between two groups at 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week.

257 Table 4 The statistical analysis result of the metabolites in fecal extracts of control and model  
 258 group at 4<sup>th</sup>, 6<sup>th</sup> and 8<sup>th</sup> week.

metabolites	chemical shift	variations		
		4 <sup>th</sup> week	6 <sup>th</sup> week	8 <sup>th</sup> week
n-butyrate	0.90(t) 1.56(m) 2.16(t)	↓*	↑*	↑*
propionate	1.06(t)	-	↓*	↓**
alanine	1.48(d)	↑*	↑*	↑**
acetate	1.92(s)	↓*	↓*	↓**
glutamate	2.35(m)	↑*	↑**	↑**
succinate	2.41(s)	↓*	↓**	-
taurine	3.27(t) 3.43(t)	↓*	↓**	↓**
glycerol	3.65(dd)	-	↓**	↓**

259 \*: to compare with controls \*  $p < 0.05$ ; \*\*  $p < 0.01$ .

#### 260 4. Discussion

261 The fructose-fed IR models used in our study have been previously found to be  
 262 appropriate for researching insulin resistance associated with high fructose  
 263 consumption.<sup>8,9</sup> From Table 1, we found that excessive consumption of fructose  
 264 induced insulin resistance, which were in accordance with the previous studies.<sup>13</sup>  
 265 Combined with pattern recognition techniques, we have applied <sup>1</sup>H NMR based  
 266 metabonomics of urine, plasma and fecal extracts to discriminate the fructose-fed IR  
 267 model group from the control group, suggesting the fructose feeding can intervene in  
 268 the metabolic network, and induce the metabolic disorders.

269 The fructose-fed rats were unable to use insulin effectively, leading to impaired  
 270 glucose uptake and utilization. Consequently, the body would regulate its energy  
 271 metabolism, resulting in a systemic disorder of energy synthesis and metabolism.<sup>24</sup>  
 272 The energy needed for the body requires ATP, which primarily originates from  
 273 glycolysis, glucose and lipid oxidation. Under normal physiological conditions, the  
 274 substrates of glucose, amino acids, ketone bodies and fatty acids are utilized. However,

275 fructose feeding decreased glucose metabolism and the sensitivity to normal insulin  
276 levels. A number of metabolites involved in energy metabolism were perturbed after  
277 fructose treatment. Compared with the control group, the plasma levels of pyruvate  
278 and lactate in the model group reduced significantly. This indicated that fructose  
279 feeding induced the glycolysis disorders. The NMR spectra showed the continuous  
280 decrease of citrate and  $\alpha$ -KG in urine, the intermediate products of TCA cycle, which  
281 were indicative of alterations in energy metabolism<sup>25,26</sup> and impairments in  
282 mitochondrial function.<sup>27</sup> The reduced pyruvate revealed that the generation of  
283 acetylcoenzymeA (acetyl-CoA) was down regulated, and resulted in inhibition of  
284 Kreb's cycle. Additionally, together with the accumulation of alanine and glycine in  
285 plasma, the decreased level of pyruvate probably demonstrated the reduced  
286 production from amino acids.

287 Taurine, possessing many vital properties, such as antioxidation, osmoregulation,  
288 membrane stabilization,  $\text{Ca}^{2+}$  flux regulation, and attenuation of apoptosis,<sup>28-30</sup>  
289 decreased in urine and fecal extracts during the whole experiment, while it increased  
290 in the plasma at 8<sup>th</sup> week. Urinary taurine has long been identified as a specific marker  
291 of liver toxicity and damage,<sup>31,32</sup> including necrosis and steatosis. Liver is a  
292 metabolism place for the maintenance of lipid, glucose, and hormonal homeostasis.  
293 As such, the liver is at the crossroads of metabolic health and disease. Fructose  
294 feeding has also been shown to induce the activation of carbohydrate regulatory  
295 element-binding protein (ChREBP), and to increase the expression of lipogenic genes  
296 such as fatty acid synthase (FAS) and acyl coenzyme-A carboxylase (ACC).<sup>33</sup>  
297 Long-term fructose intake is associated with nonalcoholic fatty liver disease (NAFLD)  
298 which is another manifestation of the metabolic syndrome.<sup>34</sup> Therefore, the metabolic  
299 changes of taurine revealed the liver damage and dysfunction induced by excessive

300 consumption of fructose.<sup>33,34</sup>

301 Choline is a part of glycerophospholipids, which was activated by choline kinase  
302 and phosphocholine cytidyltransferase. The decreases of choline and PC/GPC, as  
303 important constituents of cell membranes, were found in urine at the end of 6<sup>th</sup> and 8<sup>th</sup>  
304 week, which probably demonstrated the disturbed membrane phospholipid  
305 metabolism. Choline was a primary source for methyl groups via one of its  
306 metabolites betaine that participates in the synthesis pathways.<sup>35</sup> Betaine was  
307 synthesized from glycine. So the decline level of choline probably resulted in  
308 accumulation of glycine and betaine in the urine and plasma.

309 Muscle motion requires a lot of energy, and creatinine is one of the most important  
310 materials which is the decomposition of creatine and excreted by kidney. The  
311 increased creatine/creatinine was found in fructose-fed rats' urine from 4<sup>th</sup> week to the  
312 end of 8<sup>th</sup> week compared with the controls. This result suggested that administration  
313 of fructose feeding induce the glomerular inflammation and kidney failure. The high  
314 level of TMAO, commonly associated with osmotic stress in the renal medulla and a  
315 signal of drug-induced nephrotoxicity<sup>36,37</sup> was found in fructose feeding rats. This also  
316 revealed the renal injury. The increased level of TMAO in urine from 4<sup>th</sup> week to 6<sup>th</sup>  
317 week was likely related to the fructose feeding induced disruption in intestinal flora.  
318 The reduced level of glycerol in plasma may indicate the fat metabolism disorder  
319 caused by the fructose feeding.

320 Hippurate is normally found in urine, and it is correlated with the microbial activity  
321 and composition of the gut.<sup>38,39</sup> An increased level of hippurate in the urine of  
322 fructose-fed rats was found at the end of 6<sup>th</sup> week, which was consistent with the  
323 predecessors' study.<sup>40</sup> This change indicated the disorder of gut microbiota under  
324 fructose feeding. We found that acetate increased in urine and plasma, while it

325 decreased in fecal extracts. Acetate is the final product of lipid metabolism and it can  
326 be catalyzed to acetyl-Coenzyme A (acetyl-CoA) by acetyl-CoA synthetase.<sup>41</sup>  
327 Therefore, the increased level of acetate in urine and plasma reflected an accelerated  
328 lipid catabolism as a consequence of perturbed energy metabolism. Acetate,  
329 propionate and n-butyrate are the major short chain fatty acids (SCFAs) produced  
330 during fermentation by gut bacteria. Dolara et al have demonstrated that lower  
331 concentrations of SCFAs in feces are associated with higher rates of colonic mucosal  
332 proliferation, which directly related to increased risk of colon cancer.<sup>42</sup> The significant  
333 decline of acetate and propionate in fecal extracts suggested that fructose feeding  
334 possibly increased the risk of colorectal cancer. N-butyrate is regarded as an important  
335 energy source for colonic epithelial cells of the host.<sup>43</sup> SCFAs can reflect the activity  
336 and metabolism of intestinal anaerobic bacteria indirectly. Under normal circumstance,  
337 only less than 5% of SCFAs will appear in feces. That is because, after being digested  
338 and absorbed by small intestine, the digestion will enter the cecum which is rich in  
339 carbon and nitrogen source for bacterial fermentation and utilization, and produce a  
340 large number of SCFAs in the action of bacteria in cecum. These SCFAs move to the  
341 far end direction of colon with the digestion. A large number of SCFAs are reabsorbed  
342 by colon in this process. In fecal extracts n-butyrate decreased at 4<sup>th</sup> week and  
343 increased from 6<sup>th</sup> week to the end of the 8<sup>th</sup> week, which indicated fructose feeding  
344 may induce the intestinal flora disturbance and the colonic re-absorption dysfunction.

345 A time-dependent increase in the fecal extracts of alanine reveals a higher presence  
346 of potential inhibitors of the uracil transporters in the jejunum of fructose-fed rats,  
347 which actively transports uracil from mucosa to serum. As one of amino acids to  
348 construct protein, glutamate is the very important nutrients in humans and animals.<sup>44</sup>  
349 Many factors can affect the levels of glutamate presented in fecal extracts, such as the

350 absorption of the gut epithelium and the metabolism of gut microbiota. The increased  
351 levels of glutamate in fecal extracts possibly suggest the gut epithelium dysfunction  
352 and the intestinal flora disorder.

## 353 **5. Conclusion**

354  $^1\text{H}$  NMR metabonomics in conjunction with pattern recognition and statistical  
355 analyses of urine, plasma and fecal extracts revealed a number of complex  
356 disturbances in the endogenous metabolites, which could be related to excessive  
357 fructose feeding. Amino acid metabolism, energy and gut microbiota metabolism,  
358 together with possible liver and kidney injure, could be affected by fructose feeding. It  
359 is concluded that  $^1\text{H}$  NMR-based metabonomics is a very useful approach for  
360 demonstrating the biochemical changes to monitor the progression of IR from a  
361 systematic and holistic view.

## 362 **Acknowledge**

363 We acknowledge the financial supports from the National Natural Science  
364 Foundation of China (21005022, 81274059, 81274060, 81073024), and the  
365 Guangdong Natural Science Foundation (S2011010002512).

## 366 **Reference**

- 367 1 P. Zimmet, K. G. M. M. Alberti and J. Shaw, *Nature*, 2001, 414, 782-787.
- 368 2 S. A. Isezuo, *Niger. Postgrad. Med. J.*, 2006, 13, 247-255.
- 369 3 E. J. M. Feskens, S. M. Virtanen, L. Räsänen, J. Tuomilehto, J. Stengård, J.  
370 Pekkanen, A. Nissinen and D. Kromhout, *Diabetes. Care.*, 1995, 18, 1104-1112.
- 371 4 I. S. Hwang, H. Ho, B. B. Hoffman and G. M. Reaven, *Hypertension*, 1987, 10,  
372 512-516.
- 373 5 H. Basciano, L. Federico and K. Adeli, *Nutr. Metab.*, 2005, 2, 2-5.
- 374 6 G. A. Bray, S. J. Nielsen and B. M. Popkin, *Am. J. Clin. Nutr.*, 2004, 79, 537-543.

- 375 7 R. Kohen-Avramoglu, A. Theriault and K. Adeli, *Clin. Biochem.*, 2003, 36,  
376 413-420.
- 377 8 M. M. Abdullah, N. N. Riediger, Q. L. Chen, Z. H. Zhao, N. Azordegan, Z. Y. Xu,  
378 G. Fischer, R. A. Othman, G. N. Pierce, P. S. Tappia, J. T. Zou and M. H.  
379 Moghadasian, *Mol. Cell. Biochem.*, 2009, 327, 247-256.
- 380 9 H. O. El Mesallamy, E. El-Demerdash, L. N. Hammad and H. M. El Magdoub,  
381 *Diabetol. Metab. Syndr.*, 2010, 2, 46-56.
- 382 10 F. Hosseini-Esfahani, Z. Bahadoran, P. Mirmiran, S. Hosseinpour-Niazi, F.  
383 Hosseinpanah and F. Azizi, *Nutr. Metab.*, 2011, 8, 50-57.
- 384 11 B. Cannizzo, A. Lujan, N. Estrella, C. Lembo, M. Cruzado and C. Castro, *Exp.*  
385 *Diabetes. Res.*, 2012, 2012, 1304-1312.
- 386 12 F. Briand, Q. Thiéblemont, E. Muzotte and T. Sulpice, *J. Nutr.*, 2012, 142,  
387 704-709.
- 388 13 J. K. Nicholson, J. C. Lindon and E. Holmes, *Xenobiotica*, 1999, 29, 1181-1189.
- 389 14 P. Wang, H. Sun, H. T. Lv, W. J. Sun, Y. Yuan, Y. Han, D. W. Wang, A. H.  
390 Zhang and X. J. Wang, *J. Pharm. Biomed. Anal.*, 2010, 53, 631-645.
- 391 15 P. Bernini, I. Bertini, C. Luchinat, L. Tenori and A. Tognaccini, *J. Proteome. Res.*,  
392 2011, 10, 4983-4992.
- 393 16 J. B. Peng, H. M. Jia, T. Xu, Y. T. Liu, H. W. Zhang, L. L. Yu, D. Y. Cai and Z. M.  
394 Zou, *Process. Biochem.*, 2011, 46, 2240-2247.
- 395 17 M. F. Mahmoud, M. El-Nagar and H. M. El-Bassossy, *Arch. Pharm. Res.*, 2012, 35,  
396 155-162.
- 397 18 Y. Zhao, J. F. Wu, J. V. Li, N. Y. Zhou, H. R. Tang and Y. L. Wang, *J. Proteome.*  
398 *Res.*, 2013, 12, 2987-2999.
- 399 19 D. Barham and P. Trinder, *Analyst*, 1972, 97, 142-145.

- 400 20 D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher and R.  
401 C. Turner, *Diabetologia*, 1985, 28, 412-419.
- 402 21 X. J. Zhao, C. Y. Huang, H. H. Lei, X. Nie, H. R. Tang and Y. L. Wang, *J.*  
403 *Proteome. Res.*, 2011, 10, 5183-5190.
- 404 22 J. K. Nicholson, P. J. Foxall, M. Spraul, R. D. Farrant and J. C. Lindon, *Anal.*  
405 *Chem.*, 1995, 67, 793-811.
- 406 23 G. Le Gall, S. O. Noor, K. Ridgway, L. Scovell, C. Jamieson, I. T. Johnson, I. J.  
407 Colquhoun, E. K. Kemsley and A. Narbad, *J. Proteome. Res.*, 2011, 10, 4208-4218.
- 408 24 D. An and B. Rodrigues, *Am. J. Physiol. Heart. Circ. Physiol.*, 2006, 291,  
409 1489–1506.
- 410 25 W. J. Cong, Q. L. Liang, L. Li, J. Shi, Q. F. Liu, Y. Feng, Y. M. Wang and G. A.  
411 Luo, *Talanta*, 2012, 89, 91-98.
- 412 26 M. X. Yang, S. Wang, F. H. Hao, Y. J. Li, H. R. Tang and X. M. Shi, *Talanta*, 2012,  
413 88, 136-144.
- 414 27 N. J. Waters, C. J. Waterfield, R. D. Farrant, E. Holmes and J. K. Nicholson, *Chem.*  
415 *Res. Toxicol.*, 2005, 18, 639-654.
- 416 28 J. H. Wang, H. P. Redmond, R. W. Watson, C. Condrón and D. Bouchier-Hayes,  
417 *Shock*, 1996, 6, 331-338.
- 418 29 C. Condrón, P. Neary, D. Toomey, H. P. Redmond and D. Bouchier- Hayes, *Shock*,  
419 2003, 19, 564-569.
- 420 30 S. G. Maher, C. E. Condrón, D. J. Bouchier-Hayes and D. M. Toomey, *Clin. Exp.*  
421 *Immunol.*, 2005, 139, 279–286.
- 422 31 C. J. Waterfield, J. A. Turton, M. D. Scales and J. A. Timbrell, *Arch. Toxicol.*,  
423 1993, 67, 244-254.
- 424 32 T. A. Clayton, J. C. Lindon, J. R. Everett, C. Charuel, G. Hanton, J. L. Le Net, J. P.



- 425 Provost and J. K. Nicholson, *Arch. Toxicol.*, 2003, 77, 208-217.
- 426 33 R. Rodríguez-Calvo, E. Barroso, L. Serrano, T. Coll, R. M. Sánchez, M. Merlos, X.  
427 Palomer, J. C. Laguna and M. Vázquez-Carrera, *Hepatology.*, 2009, 49, 106-115.
- 428 34 X. Ouyang, P. Cirillo, Y. Sautin, S. McCall, J. L. Bruchette, A. M. Diehl, R. J.  
429 Johnson and M. F. Abdelmalek, *J. Hepatol.*, 2008, 48, 993-999.
- 430 35 P. I. Holm, P. M. Ueland, G. Kvalheim and E. A. Lien, *Clin. Chem.*, 2003, 49,  
431 286-294.
- 432 36 J. Feng, X. Li, F. Pei, X. Chen, S. Li and Y. Nie, *Analytical. Biochemistry.*, 2002,  
433 301, 1-7.
- 434 37 P. J. Foxall, G. J. Mellotte, M. R. Bending, J. C. Lindon and J. K. Nicholson,  
435 *Kidney. International.*, 1993, 43, 234-245.
- 436 38 N. G. Psihogios, I. F. Gazi, M. S. Elisaf, K. I. Seferiadis and E. T. Bairaktari,  
437 *NMR. Biomed.*, 2008, 21, 195-207.
- 438 39 L. Wei, P. Q. Liao, H. F. Wu, X. J. Li, F. K. Pei, W. S. Li and Y. J. Wu, *Toxicol.*  
439 *Appl. Pharmacol.*, 2009, 234, 314–325.
- 440 40 L. C. Zhao, X Liu, L. Y. Xie, H. C. Gao and D. H. Lin, *Anal. Sci.*, 2010, 26,  
441 1277-1282.
- 442 41 S. Kumari, R. Tishel, M. Eisenbach and A. J. Wolfe, *J. Bacteriol.*, 1995, 177,  
443 2878-2886.
- 444 42 P. Dolaro, G. Caderni, M. Salvadori, G. Morozzi, R. Fabiani, A. Cresci, C.  
445 Orpianesi, G. Trallori, A. Russo and D. Palli, *Nutr. Cancer.*, 2002, 42, 186-190.
- 446 43 T. L. Miller and M. J. Wolin, *Appl. Environ. Microbiol.*, 1996, 62, 1589-1592.
- 447 44 G. Andersen, B. Andersen, D. Dobritzsch, K. D. Schnackerz and J. Piskur, *FEBS.*  
448 *J.*, 2007, 274, 1804–1817.